IL148980A0 - An antibody to human tissue factor and experimental animals having inserted cells with the gene encoding human tissue factor - Google Patents
An antibody to human tissue factor and experimental animals having inserted cells with the gene encoding human tissue factorInfo
- Publication number
- IL148980A0 IL148980A0 IL14898000A IL14898000A IL148980A0 IL 148980 A0 IL148980 A0 IL 148980A0 IL 14898000 A IL14898000 A IL 14898000A IL 14898000 A IL14898000 A IL 14898000A IL 148980 A0 IL148980 A0 IL 148980A0
- Authority
- IL
- Israel
- Prior art keywords
- tissue factor
- human tissue
- antibody
- gene encoding
- experimental animals
- Prior art date
Links
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 title abstract 4
- 238000010171 animal model Methods 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 201000005665 thrombophilia Diseases 0.000 abstract 2
- 200000000007 Arterial disease Diseases 0.000 abstract 1
- 206010003178 Arterial thrombosis Diseases 0.000 abstract 1
- 206010020880 Hypertrophy Diseases 0.000 abstract 1
- 206010047249 Venous thrombosis Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 210000004231 tunica media Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/106—Primate
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Environmental Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Ecology (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP28184399 | 1999-10-01 | ||
JP28213499 | 1999-10-01 | ||
JP28216799 | 1999-10-01 | ||
JP28212099 | 1999-10-01 | ||
JP28219299 | 1999-10-01 | ||
JP28218899 | 1999-10-01 | ||
PCT/JP2000/006802 WO2001024626A1 (fr) | 1999-10-01 | 2000-09-29 | Prevention et traitement de maladies associees a la coagulation sanguine |
Publications (1)
Publication Number | Publication Date |
---|---|
IL148980A0 true IL148980A0 (en) | 2002-11-10 |
Family
ID=27554423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14898000A IL148980A0 (en) | 1999-10-01 | 2000-09-29 | An antibody to human tissue factor and experimental animals having inserted cells with the gene encoding human tissue factor |
Country Status (18)
Country | Link |
---|---|
US (2) | US8062638B1 (hu) |
EP (2) | EP1222854B1 (hu) |
JP (1) | JP3859512B2 (hu) |
KR (1) | KR20030008205A (hu) |
AT (1) | ATE498305T1 (hu) |
AU (1) | AU7450600A (hu) |
BR (1) | BR0014667A (hu) |
CA (1) | CA2388408A1 (hu) |
CZ (1) | CZ20021035A3 (hu) |
DE (1) | DE60045638D1 (hu) |
DK (1) | DK1222854T3 (hu) |
HU (1) | HUP0203486A2 (hu) |
IL (1) | IL148980A0 (hu) |
MX (1) | MXPA02003278A (hu) |
NO (1) | NO20021410L (hu) |
PL (1) | PL354961A1 (hu) |
SK (1) | SK4442002A3 (hu) |
WO (1) | WO2001024626A1 (hu) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6703494B2 (en) | 2000-03-16 | 2004-03-09 | Genentech, Inc. | Anti-tissue factor antibodies with enhanced anticoagulant potency |
US20040180051A1 (en) * | 2001-03-26 | 2004-09-16 | Koji Suzuki | Blood rheology improving agents |
JP4683821B2 (ja) | 2001-05-18 | 2011-05-18 | 中外製薬株式会社 | ヒト組織因子を産生するノックイン非ヒト動物 |
PL368989A1 (en) * | 2001-10-02 | 2005-04-04 | Novo Nordisk A/S | Human tissue factor antibodies |
US20060233786A1 (en) * | 2002-05-23 | 2006-10-19 | Chugai Seiyaku Kabushiki Kaisha | Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation |
EP1598074B1 (en) | 2003-02-28 | 2019-01-02 | Chugai Seiyaku Kabushiki Kaisha | Stabilized protein-containing formulations |
US7605235B2 (en) | 2003-05-30 | 2009-10-20 | Centocor, Inc. | Anti-tissue factor antibodies and compositions |
EP1939218A1 (en) * | 2006-12-29 | 2008-07-02 | Thrombotargets Europe, S.L. | Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof |
US8722044B2 (en) | 2011-03-15 | 2014-05-13 | Janssen Biotech, Inc. | Human tissue factor antibody and uses thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58201994A (ja) | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
IE81149B1 (en) * | 1987-02-12 | 2000-05-03 | Genentech Inc | Methods and deoxyribonucleic acid for the preparation of tissue factor protein |
US5223427A (en) * | 1987-03-31 | 1993-06-29 | The Scripps Research Institute | Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain |
WO1988009817A1 (en) * | 1987-06-12 | 1988-12-15 | Mount Sinai School Of Medicine Of The City Univers | Cloning and expression of human tissue factor |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
ES2134212T3 (es) | 1991-04-25 | 1999-10-01 | Chugai Pharmaceutical Co Ltd | Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano. |
US5346991A (en) * | 1991-06-13 | 1994-09-13 | Genentech, Inc. | Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
US5879677A (en) * | 1992-12-09 | 1999-03-09 | The Scripps Research Institute | Method for inhibition of cerebral tissue factor mediated reperfusion damage |
AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
JP3865418B2 (ja) | 1994-07-13 | 2007-01-10 | 中外製薬株式会社 | ヒトインターロイキン−8に対する再構成ヒト抗体 |
CA2194907A1 (en) | 1994-07-13 | 1996-02-01 | Kouji Matsushima | Reshaped human antibody against human interleukin-8 |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
AU744146B2 (en) | 1996-09-26 | 2002-02-14 | Chugai Seiyaku Kabushiki Kaisha | Antibody against human parathormone related peptides |
US5986065A (en) | 1997-03-10 | 1999-11-16 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
BR9909382A (pt) * | 1998-04-03 | 2000-12-05 | Chugai Pharmaceutical Co Ltd | Anticorpo humanizado contra o fator tissular humano (tf) e processo de produção de anticorpo humanizado |
EP0987274A1 (en) * | 1998-09-15 | 2000-03-22 | Hoechst Marion Roussel Deutschland GmbH | Factor VIIa Inhibitors |
-
2000
- 2000-09-29 WO PCT/JP2000/006802 patent/WO2001024626A1/ja not_active Application Discontinuation
- 2000-09-29 DK DK00963006.2T patent/DK1222854T3/da active
- 2000-09-29 MX MXPA02003278A patent/MXPA02003278A/es unknown
- 2000-09-29 BR BR0014667-6A patent/BR0014667A/pt not_active IP Right Cessation
- 2000-09-29 EP EP00963006A patent/EP1222854B1/en not_active Expired - Lifetime
- 2000-09-29 AU AU74506/00A patent/AU7450600A/en not_active Abandoned
- 2000-09-29 SK SK444-2002A patent/SK4442002A3/sk unknown
- 2000-09-29 PL PL00354961A patent/PL354961A1/xx unknown
- 2000-09-29 HU HU0203486A patent/HUP0203486A2/hu unknown
- 2000-09-29 JP JP2001527640A patent/JP3859512B2/ja not_active Expired - Fee Related
- 2000-09-29 KR KR1020027004130A patent/KR20030008205A/ko not_active Application Discontinuation
- 2000-09-29 CZ CZ20021035A patent/CZ20021035A3/cs unknown
- 2000-09-29 EP EP10180790A patent/EP2351483A1/en not_active Withdrawn
- 2000-09-29 AT AT00963006T patent/ATE498305T1/de not_active IP Right Cessation
- 2000-09-29 CA CA002388408A patent/CA2388408A1/en not_active Abandoned
- 2000-09-29 IL IL14898000A patent/IL148980A0/xx unknown
- 2000-09-29 DE DE60045638T patent/DE60045638D1/de not_active Expired - Lifetime
- 2000-09-29 US US10/089,501 patent/US8062638B1/en not_active Expired - Fee Related
-
2002
- 2002-03-21 NO NO20021410A patent/NO20021410L/no not_active Application Discontinuation
-
2011
- 2011-10-04 US US13/252,455 patent/US20120073002A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20030008205A (ko) | 2003-01-24 |
JP3859512B2 (ja) | 2006-12-20 |
PL354961A1 (en) | 2004-03-22 |
EP1222854B1 (en) | 2011-02-16 |
AU7450600A (en) | 2001-05-10 |
SK4442002A3 (en) | 2003-04-01 |
CA2388408A1 (en) | 2001-04-12 |
DK1222854T3 (da) | 2011-03-14 |
US8062638B1 (en) | 2011-11-22 |
BR0014667A (pt) | 2002-07-02 |
NO20021410D0 (no) | 2002-03-21 |
WO2001024626A1 (fr) | 2001-04-12 |
EP1222854A1 (en) | 2002-07-17 |
NO20021410L (no) | 2002-05-24 |
ATE498305T1 (de) | 2011-03-15 |
EP1222854A4 (en) | 2006-07-05 |
CZ20021035A3 (cs) | 2002-08-14 |
DE60045638D1 (de) | 2011-03-31 |
HUP0203486A2 (hu) | 2003-02-28 |
MXPA02003278A (es) | 2002-09-02 |
US20120073002A1 (en) | 2012-03-22 |
EP2351483A1 (en) | 2011-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA03010085A (es) | Composiciones y su uso en la hiperplasia. | |
WO2003096990A3 (en) | Protein cages for the delivery of medical imaging and therapy | |
AU6157901A (en) | Delivery systems for treatment of vascular disease | |
BR9710682A (pt) | Composi-{es e m-todos para tratar ou prevenir doen-as das vias do organismo | |
MXPA03008623A (es) | Combinacion farmaceutica para el tratamiento del cancer. | |
EA200200990A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы дельта человека | |
HUT76258A (en) | Compositions comprising dna damaging agents and p53, and methods for uses thereof | |
AU2406402A (en) | Substituted benzene derivatives or salts thereof | |
HK1064950A1 (en) | Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s) | |
IL148980A0 (en) | An antibody to human tissue factor and experimental animals having inserted cells with the gene encoding human tissue factor | |
EA200300849A1 (ru) | Способы лечения или профилактики кожных заболеваний с помощью cd2-связывающих агентов | |
DE60020681D1 (de) | Zusammensetzungen und verfahren zur verbesserung der integrität von angegriffenen körperpassagewegen und höhlen | |
EP0651655A4 (en) | REDUCTION OF MICROVASCULAR BLEEDING DURING SURGERY BY BLOCKING PROTEIN C ACTIVATION | |
WO2003063725A3 (en) | Methods of preventing and treating flavivirus infection in animals | |
EP1266663A4 (en) | EOSINOPHILE SPECIFIC APOPTOSE INDUCTORS | |
AU2251302A (en) | Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 | |
PT1187612E (pt) | Utilizacao do riluzole para o tratamento da esclerose multipla | |
EP0950416A4 (en) | Preventive and / or therapeutic agent against cachexia | |
WO2001089558A3 (en) | Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states | |
WO2006007710A3 (en) | Acute inflammatory condition treatment | |
PL365565A1 (en) | Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies | |
WO2001096398A3 (en) | Uncoupling proteins as targets for the treatment of heart failure | |
IL143279A0 (en) | Novel therapeutic application of low molecular weight heparin | |
UA49496A (uk) | Спосіб лікування уражень суглобів при ревматичних захворюваннях | |
ATE327736T1 (de) | Liposomenhaltiges mittel zur behandlung gefässerkrankungen |